Walnut, CA—Farlong Pharmaceutical has completed a three-year clinical trial to determine the effects of Farlong NotoGinseng, according to a press release.
The randomized, placebo-controlled, double-blind, parallel study was performed on 100 adults between December 2016 and June 2019. It sought to determine the effect of Farlong’s branded Panax notoginseng extract on cholesterol and blood pressure.
Over a 12 week period, the participants were given one serving of the product or the placebo to take orally at the same time every day, 30 minutes before a meal, for 84 days. From baseline to week eight, the NotoGinseng group saw a significant decrease in serum low-denisty lipoprotein (LDL) cholesterol, the ‘bad’ cholesterol. Following 12 weeks of supplementation, the test group saw a slight increase in high-density lipoprotein (HDL) cholesterol, the ‘good’ cholesterol. The test group also saw decreases in both systolic and diastolic blood pressures.
The placebo group, in comparison, had a decrease in HDL cholesterol, and saw increases in systolic and diastolic blood pressures.